Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bacteriophage cocktail (anti-Pseudomonas aeruginosa)
- Development stage
- Preclinical
- Lead developer
- CHU de Besançon
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Inhalation, Intravenous, Topical
01
Overview
The anti-Pseudomonas aeruginosa bacteriophage cocktail is a therapeutic preparation of lytic bacteriophages developed under the THERAPhage project (part of the PHAGEinLYON program) by Hospices Civils de Lyon and CHU de Besançon. The cocktail is designed to target and lyse multidrug-resistant (MDR) strains of Pseudomonas aeruginosa, a major opportunistic pathogen associated with community-acquired and nosocomial respiratory, bone, and joint infections. The cocktail incorporates highly active and complementary phages, including the jumbo phage V1PA01 (Phikzvirus), V4PA08 (Pakpunavirus), V1PA18 (Pakpunavirus), and V1PA05 (Pbunavirus), which collectively cover a broad spectrum of clinical isolates. To overcome bacterial resistance and expand the host range to high-risk MDR sequence types (such as ST175, ST253, ST274, ST309, and ST395), the developers employ phage training (directed evolution via the Appelmans protocol) to generate evolved phage subpopulations with enhanced lytic activity.
- Other names
- anti-Pseudomonas aeruginosa phage cocktailPHAGEinLYON anti-Pseudomonas aeruginosa cocktailTHERAPhage anti-Pseudomonas aeruginosa cocktail
02
Targets
P. aeruginosa (Pseudomonas aeruginosa)
Beyond the preview
Go deeper on bacteriophage cocktail (anti-Pseudomonas aeruginosa).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bacteriophage cocktail (anti-Pseudomonas aeruginosa).